Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis

By C. Lee, J. Man, S. Lord, M. Links, V. Gebski, T. Mok, Jie Yang. Journal of Thoracic Oncology, 2017

808 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2016, background): “A small meta-analysis of second-line immune checkpoint therapy versus chemotherapy (not included in the systematic review) suggested immune checkpoint inhibitors do not improve median OS in patients with EGFR-sensitizing mutated NSCLCwhen compared with docetaxel.(36) D.”
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study (2019, result): “The association between EGFR mutation and shorter median OS and lower 5-year OS rate among previously treated patients is consistent with the findings from a meta-analysis of three studies in previously treated patients (nivolumab v docetaxel [CheckMate-057]; pembrolizumab v docetaxel [KEYNOTE-010];”
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry (2019, background): “A recent meta-analysis including three randomized trials of immunotherapy in TKI-pretreated patients reported that ICI do not improve OS compared with docetaxel in patients with EGFRmutant NSCLC [25].”